Healthcare provider profile · identity verified

Ellen F Liuzza, MD

Internal Medicine · OAK RIDGE, TN · NPI 1437158920

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	460	117
Atorvastatin Calcium	Atorvastatin Calcium	407	114
Pravastatin Sodium	Pravastatin Sodium	316	86
Amlodipine Besylate	Amlodipine Besylate	273	86
Lisinopril	Lisinopril	264	74
Losartan Potassium	Losartan Potassium	255	69
Omeprazole	Omeprazole	239	70
Gabapentin	Gabapentin	147	43
Pantoprazole Sodium	Pantoprazole Sodium	139	42
Escitalopram Oxalate	Escitalopram Oxalate	133	35
Metformin Hcl	Metformin Hcl	123	36
Metoprolol Succinate	Metoprolol Succinate	122	37
Potassium Chloride	Potassium Chloride	112	38
Rosuvastatin Calcium	Rosuvastatin Calcium	104	30
Sertraline Hcl	Sertraline Hcl	104	28
Albuterol Sulfate Hfa	Albuterol Sulfate	103	37
Simvastatin	Simvastatin	103	29
Trazodone Hcl	Trazodone Hcl	99	28
Montelukast Sodium	Montelukast Sodium	98	26
Alendronate Sodium	Alendronate Sodium	93	30
Furosemide	Furosemide	91	30
Hydrochlorothiazide	Hydrochlorothiazide	87	26
Famotidine	Famotidine	84	31
Meloxicam	Meloxicam	79	26
Metoprolol Tartrate	Metoprolol Tartrate	73	21
Allopurinol	Allopurinol	71	24
Clopidogrel	Clopidogrel Bisulfate	66	15
Synthroid	Levothyroxine Sodium	64	18
Methylprednisolone	Methylprednisolone	62	52
Ozempic	Semaglutide	59	17
Tamsulosin Hcl	Tamsulosin Hcl	58	20
Fluticasone Propionate	Fluticasone Propionate	57	16
Zolpidem Tartrate	Zolpidem Tartrate	56	13
Ezetimibe	Ezetimibe	54	16
Bumetanide	Bumetanide	53	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	51	20
Nystatin	Nystatin	51	30
Esomeprazole Magnesium	Esomeprazole Magnesium	48	14
Carvedilol	Carvedilol	47	13
Eliquis	Apixaban	46	12
Metformin Hcl Er	Metformin Hcl	46	17
Estradiol	Estradiol	45	20
Hydroxyzine Hcl	Hydroxyzine Hcl	45	15
Glimepiride	Glimepiride	42	11
Ropinirole Hcl	Ropinirole Hcl	42	14
Buspirone Hcl	Buspirone Hcl	41	12
Mounjaro	Tirzepatide	41	suppressed
Duloxetine Hcl	Duloxetine Hcl	40	12
Celecoxib	Celecoxib	39	12
Lorazepam	Lorazepam	39	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	38	suppressed
Spironolactone	Spironolactone	38	18
Alprazolam	Alprazolam	37	12
Bupropion Xl	Bupropion Hcl	37	12
Tramadol Hcl	Tramadol Hcl	37	12
Fluoxetine Hcl	Fluoxetine Hcl	35	11
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Ramipril	Ramipril	34	12
Prolia	Denosumab	33	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Ibandronate Sodium	Ibandronate Sodium	27	suppressed
Gemfibrozil	Gemfibrozil	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Lovastatin	Lovastatin	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	21
Valsartan	Valsartan	22	suppressed
Trulicity	Dulaglutide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Ondansetron Odt	Ondansetron	20	15
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	11
Atenolol	Atenolol	19	suppressed
Mometasone Furoate	Mometasone Furoate	19	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Ondansetron Hcl	Ondansetron Hcl	17	16
Pregabalin	Pregabalin	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	12
Benazepril Hcl	Benazepril Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Prednisone	Prednisone	15	11
Telmisartan	Telmisartan	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Metronidazole	Metronidazole	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Azithromycin	Azithromycin	12	12
Myrbetriq	Mirabegron	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Topiramate	Topiramate	12	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Testosterone	Testosterone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error